Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program
The presence of tumor cells in cerebrospinal fluid may be an indicator of brain metastases, which occur when cancer has spread to the central nervous system.
The poster presentation today reported higher sensitivity with Target Selector™ in detecting cancer material and identifying leptomeningeal metastases (cancer in the thin layers of tissue that cover and protect the brain and spinal cord) in cerebrospinal fluid compared with cerebrospinal fluid cytology, the standard-of-care technology.
"Cerebrospinal fluid cytology for the detection of leptomeningeal metastases is the standard, but it often results in false negative results, and lacks sensitivity in detecting biomarkers. These results show
"We are excited to share these data at ASCO as they support our belief that Target Selector™ has potential applicability for identifying actionable mutations in patients with brain metastases allowing physicians the choice to test cerebrospinal fluid, blood or both when looking for biomarker information in order to choose the most appropriate therapy," said
"We'd like to thank
A medical procedure known as a spinal tap or lumbar puncture is typically performed to collect cerebrospinal fluid when cancer patients present with central nervous system symptoms, for example confusion or dementia. More than 200,000 of these procedures are performed annually in the
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the promise of
LHA Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/data-affirming-biocepts-target-selector-platform-identifies-cancer-mutations-in-cerebrospinal-fluid-presented-at-asco-2020-virtual-scientific-program-301067499.html